Home > Insider Trading > Filing (0000921895-14-002678)

Filing Details

Accession Number:: 0000921895-14-002678
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-12-17 18:10:54
Reporting Period:: 2014-12-15

Filing Date:: 2014-12-17
Accepted Time:: 2014-12-17 18:10:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1412067	Oncothyreon Inc.	ONTY	Services-Commercial Physical & Biological Research (8731)	260868560

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
918923	P L Fund Value Biotechnology	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	No	Yes
1055947	P/Il L Partners Bvf	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	Yes	No
1056807	Bvf Inc/Il	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	Yes	No
1102444	Biotechnology Value Fund Ii Lp	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	No	Yes
1233840	N Mark Lampert	One Sansome Street 30Th Floor San Francisco CA 94104	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2014-12-15	145,515	$1.88	6,264,385	No	4	P	Indirect	By Biotechnology Value Fund, L.P.
Common Stock, $0.0001 Par Value	Acquisiton	2014-12-15	79,434	$1.88	3,243,096	No	4	P	Indirect	By Biotechnology Value Fund II, L.P.
Common Stock, $0.0001 Par Value	Acquisiton	2014-12-17	98,298	$1.73	6,362,683	No	4	P	Indirect	By Biotechnology Value Fund, L.P.
Common Stock, $0.0001 Par Value	Acquisiton	2014-12-17	55,197	$1.73	3,298,293	No	4	P	Indirect	By Biotechnology Value Fund II, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Biotechnology Value Fund, L.P.
No	4	P	Indirect	By Biotechnology Value Fund II, L.P.
No	4	P	Indirect	By Biotechnology Value Fund, L.P.
No	4	P	Indirect	By Biotechnology Value Fund II, L.P.

Footnotes

This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert. (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock pursuant to Rule 16a-1(a)(1). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Represents securities owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
Represents securities owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
Amount may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request.